JP2008509998A - 改良された光増感剤処方物およびそれらの用途 - Google Patents
改良された光増感剤処方物およびそれらの用途 Download PDFInfo
- Publication number
- JP2008509998A JP2008509998A JP2007527830A JP2007527830A JP2008509998A JP 2008509998 A JP2008509998 A JP 2008509998A JP 2007527830 A JP2007527830 A JP 2007527830A JP 2007527830 A JP2007527830 A JP 2007527830A JP 2008509998 A JP2008509998 A JP 2008509998A
- Authority
- JP
- Japan
- Prior art keywords
- photosensitizer
- formulation
- thpc
- pdt
- low concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
【解決手段】疎水性光増感剤および該疎水性光増感剤を可溶化するアルコール性賦形剤混合物からなる処方物であって、ここで該光増感剤は周知のPDI光増感剤組成物または薬剤より実質的に少ない量で存在し、そして光力学治療療法に関する性質が向上している高増殖性組織疾患の光力学治療に有用な低濃度光増感剤処方物。
【選択図】なし
Description
光増感剤の投与と照射との間の間隔(医薬−光の間隔または「DLI」)を短縮する光増感剤処方物および光力学治療法を提供するのが本発明の他の目的である。
周知の光増感剤組成物および方法よりも低下した激しい副作用を生ずる光増感剤処方物を提供するのが本発明の別の目的である。
本発明の上記および他の目的、特徴および利点は、以下の既述から明らかになるだろう。
1)上記のように低濃度処方物を投与することにより光増感剤の予め選択された投与量(体重1kgあたりmg)を治療域に投与する段階。
2)光増感剤が選択的にターゲット高増殖性組織に蓄積するのに十分な時間経過させる段階。
本発明の1つの態様における医薬−光の間隔(DLI)は、光増感剤の投与後5−48時間に及ぶ。正確なDLIは、光増感剤と特定の治療との間を変化し、それは当業者に一般に周知である。本発明の方法の他の好ましい態様では、1−24時間のDLIが最適である。
本発明は、以下の実施例によりさらに説明されるが、それにより本発明を制限するものではない。
測定点 時間点(測定された蛍光/テストされた患者)
15分 1時間 3時間 1日 2日
腫瘍 0/11 0/11 4/11 すべて すべて
病巣周囲の皮膚 0/11 0/11 2/11 10/11 すべて
無傷の皮膚 0/11 0/11 2/11 8/11 9/11
測定点 時間点(測定された蛍光/テストされた患者)
15分 1時間 3時間 1日 2日
腫瘍 0/16 5/16 12/16 すべて すべて
病巣周囲の皮膚 0/16 2/16 11/16 すべて すべて
無傷の皮膚 0/16 0/16 10/16 すべて すべて
測定点 時間点(測定された蛍光/テストされた患者)
15分 1時間 3時間 1日 2日
腫瘍 0/11 0/11 4/11 すべて すべて
病巣周囲の皮膚 0/11 0/11 2/11 10/11 すべて
無傷の皮膚 0/11 0/11 2/11 8/11 9/11
測定点 時間点(測定された蛍光/テストされた患者)
15分 1時間 3時間 1日 2日
腫瘍 0/10 0/10 3/10 すべて すべて
病巣周囲の皮膚 0/10 0/10 2/10 9/10 すべて
無傷の皮膚 0/10 0/10 1/10 9/10 すべて
実施例に関連して本発明の好ましい態様を既述したが、本発明は、精密な態様に制限されず、そして種々の変化および改変が、請求の範囲に規定された本発明の範囲または趣旨から離れることなく、当業者により実施できることを理解すべきである。
Claims (7)
- 疎水性光増感剤および該疎水性光増感剤を可溶化するアルコール性賦形剤混合物からなる処方物であって、ここで該光増感剤は周知のPDI光増感剤組成物または薬剤より実質的に少ない量で存在し、そして該処方物は光力学治療療法について向上した性質を有することを特徴とする高増殖性組織疾患の光力学治療に有用な低濃度光増感剤処方物。
- 該光増感剤が周知の光増感剤組成物または薬剤の量の1/3−1/50の量で存在する請求項1の低濃度処方物。
- 該光増感剤が、ソラレン、ポルフィリン、クロリン、バクテリオクロリン、フェオホルバイド、バクテリオフェオホルバイド、フタロシアニン、および5−アミノレビュリン酸(ALA)からなる群から選ばれる請求項1の低濃度処方物。
- 該光増感剤が、m−テトラ(ヒドロキシフェニル)クロリン(m−THPC)であり、該賦形剤混合物がv/v比で3:2の精製プロピレングリコールおよびエタノールである請求項1の低濃度処方物。
- a.請求項1の低濃度処方物中の光増感剤の少なくとも1つの予め選択された投与量を投与する段階、
b.該光増感剤を高増殖性組織に選択的に蓄積させることができる時間すなわち一般に48時間より短い時間経過させる段階、および
c.該光増感剤を活性化しそして該光増感剤を組織に対して有毒になる適切に選択された波長を有する放射を該治療域に付与する段階
からなることを特徴とする疾患のPDT療法のための低濃度治療の方法。 - 経過させる時間が1−24時間の間である請求項5の方法。
- 該PDT療法が、24時間以内に開始され完了する請求項5の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60226404P | 2004-08-16 | 2004-08-16 | |
US60/602,264 | 2004-08-16 | ||
US11/153,703 US7825153B2 (en) | 2004-08-16 | 2005-06-15 | Photosensitizer formulations and their use |
US11/153703 | 2005-06-15 | ||
PCT/US2005/026051 WO2006023194A2 (en) | 2004-08-16 | 2005-07-22 | Improved photosensitizer formulations and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008509998A true JP2008509998A (ja) | 2008-04-03 |
JP5612246B2 JP5612246B2 (ja) | 2014-10-22 |
Family
ID=35800792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007527830A Expired - Fee Related JP5612246B2 (ja) | 2004-08-16 | 2005-07-22 | 改良された光増感剤処方物およびそれらの用途 |
Country Status (18)
Country | Link |
---|---|
US (2) | US7825153B2 (ja) |
EP (1) | EP1786431B1 (ja) |
JP (1) | JP5612246B2 (ja) |
KR (2) | KR101074941B1 (ja) |
CN (1) | CN101056642B (ja) |
AU (2) | AU2005277790B2 (ja) |
BR (1) | BRPI0514364B1 (ja) |
CA (1) | CA2577441C (ja) |
DK (1) | DK1786431T3 (ja) |
ES (1) | ES2552033T3 (ja) |
HU (1) | HUE026361T2 (ja) |
IL (1) | IL181300A (ja) |
MX (2) | MX2007001902A (ja) |
PL (1) | PL1786431T3 (ja) |
PT (1) | PT1786431E (ja) |
RU (1) | RU2371181C2 (ja) |
SI (1) | SI1786431T1 (ja) |
WO (1) | WO2006023194A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10311027A1 (de) * | 2003-03-13 | 2004-09-30 | Siemens Ag | Mess- und Simulationssystem für Werkzeug- oder Produktionsmaschinen |
US20070031482A1 (en) * | 2005-08-02 | 2007-02-08 | Ceramoptec Industries, Ind. | PDT treatment method for cellulites and cosmetic use |
US20080275432A1 (en) * | 2006-05-11 | 2008-11-06 | Ceramoptec Industries, Inc. | Photodynamic foam composition and sclerosis treatment |
US8180444B2 (en) * | 2007-06-22 | 2012-05-15 | Biolitec Pharma Marketing Ltd | Enhanced PhotoDynamic Therapy with immune system assist |
US20100256125A1 (en) * | 2009-04-06 | 2010-10-07 | Zila Pharmaceuticals, Inc. | Use of improved toluidine blue in photodynamic therapy |
WO2010129775A1 (en) | 2009-05-06 | 2010-11-11 | University Of Virginia Patent Foundation | Self-illuminated handheld lens for retinal examination and photography and related method thereof |
RU2521327C1 (ru) * | 2012-12-12 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения Российской Федерации" (ФГБУ "МНИОИ им. П.А. Герцена" Минздрава России) | Препарат для фотодинамической терапии и способ фотодинамической терапии рака с его использованием |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003009842A1 (fr) * | 2001-07-17 | 2003-02-06 | Steba Biotech N.V. | Formulation galenique injectable pour utilisation dan un diagnostic ou une therapie photodynamique et son procede de preparation |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017501A (en) * | 1975-10-24 | 1977-04-12 | American Cyanamid Company | Process for preparing pyridinium chloride salts of alkyl esters of 2-chloro-N-2-hydroxyethylacetamide |
ZA855561B (en) * | 1984-07-27 | 1986-03-26 | Univ Illinois | Photodynamic herbicides |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US5162519A (en) * | 1988-03-11 | 1992-11-10 | Efamol Holdings Plc | Porphyrins and cancer treatment |
GB8805849D0 (en) * | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
US4999375A (en) * | 1989-04-11 | 1991-03-12 | Hoffmann-La Roche Inc. | Psoralen reagent compositions for extracorporeal treatment of blood |
US5173504A (en) * | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
EP0552273B1 (en) * | 1990-10-12 | 1996-12-11 | Raychem Limited | Circuit protection arrangement |
US5492924A (en) * | 1993-09-24 | 1996-02-20 | Fox Chase Cancer Center | Phorbine derivatives and their use in the diagnosis and therapy of cancer |
US5576013A (en) * | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
US5616342A (en) * | 1995-04-11 | 1997-04-01 | Pdt, Inc. | Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof |
US5877165A (en) * | 1995-11-02 | 1999-03-02 | Brookhaven Science Associates | Boronated porhyrins and methods for their use |
US5895786A (en) * | 1996-05-08 | 1999-04-20 | New York Blood Center, Inc. | Method for treating viral infections |
US6270749B1 (en) * | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
WO1999004628A1 (en) * | 1997-07-28 | 1999-02-04 | Dermatolazer Technologies Ltd. | Phototherapy based method for treating pathogens and composition for effecting same |
US6609014B1 (en) * | 1999-04-14 | 2003-08-19 | Qlt Inc. | Use of PDT to inhibit intimal hyperplasia |
US6984655B1 (en) * | 2000-02-17 | 2006-01-10 | Meiji Seika Kaisha, Ltd. | Photodynamic therapy for selectively closing neovasa in eyeground tissue |
US6462192B2 (en) * | 2001-01-23 | 2002-10-08 | Miravant Pharmaceuticals, Inc. | Processes for large scale production of tetrapyrroles |
WO2002064163A2 (en) * | 2001-02-15 | 2002-08-22 | Qlt Inc. | Reduction or prevention of pdt related inflammation |
JP2004532245A (ja) * | 2001-05-15 | 2004-10-21 | ページ ダブル フォーク | 癌を治療するための生体影響性化合物の標的送達 |
CN100488965C (zh) * | 2001-06-01 | 2009-05-20 | 塞拉莫普泰克工业公司 | 用于光动力学治疗的水溶性卟啉衍生物、其用途和制备 |
EP1279676A1 (en) * | 2001-07-19 | 2003-01-29 | Institut Curie | Porphyrin derivatives for photodynamic therapy |
US7115617B2 (en) * | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
AU2002340659B2 (en) | 2001-11-09 | 2008-04-10 | Qlt Inc. | Photodynamic therapy for the treatment of hair loss |
WO2003061696A2 (en) * | 2002-01-23 | 2003-07-31 | Light Sciences Corporation | Systems and methods for photodynamic therapy |
US6949581B2 (en) * | 2003-03-21 | 2005-09-27 | Ceramoptec Industries, Inc. | Water-soluble mono-PEGylated tetrapyrrole derivatives for photodynamic therapy and method of production |
-
2005
- 2005-06-15 US US11/153,703 patent/US7825153B2/en not_active Expired - Fee Related
- 2005-07-22 PL PL05803753T patent/PL1786431T3/pl unknown
- 2005-07-22 SI SI200532023T patent/SI1786431T1/sl unknown
- 2005-07-22 KR KR1020077004392A patent/KR101074941B1/ko not_active IP Right Cessation
- 2005-07-22 RU RU2007109602/15A patent/RU2371181C2/ru active
- 2005-07-22 KR KR1020107004905A patent/KR101158192B1/ko not_active IP Right Cessation
- 2005-07-22 HU HUE05803753A patent/HUE026361T2/en unknown
- 2005-07-22 DK DK05803753.2T patent/DK1786431T3/en active
- 2005-07-22 BR BRPI0514364-0A patent/BRPI0514364B1/pt active IP Right Grant
- 2005-07-22 WO PCT/US2005/026051 patent/WO2006023194A2/en active Application Filing
- 2005-07-22 AU AU2005277790A patent/AU2005277790B2/en not_active Ceased
- 2005-07-22 JP JP2007527830A patent/JP5612246B2/ja not_active Expired - Fee Related
- 2005-07-22 MX MX2007001902A patent/MX2007001902A/es active IP Right Grant
- 2005-07-22 CN CN2005800281841A patent/CN101056642B/zh active Active
- 2005-07-22 ES ES05803753.2T patent/ES2552033T3/es active Active
- 2005-07-22 EP EP05803753.2A patent/EP1786431B1/en active Active
- 2005-07-22 PT PT58037532T patent/PT1786431E/pt unknown
- 2005-07-22 CA CA2577441A patent/CA2577441C/en active Active
-
2007
- 2007-02-13 IL IL181300A patent/IL181300A/en active IP Right Grant
- 2007-02-15 MX MX2012005452A patent/MX336390B/es unknown
-
2008
- 2008-04-04 US US12/080,767 patent/US8580839B2/en active Active
-
2009
- 2009-11-27 AU AU2009243407A patent/AU2009243407B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003009842A1 (fr) * | 2001-07-17 | 2003-02-06 | Steba Biotech N.V. | Formulation galenique injectable pour utilisation dan un diagnostic ou une therapie photodynamique et son procede de preparation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4753958A (en) | Photochemotherapy of epithelial diseases with derivatives of hematoporphyrins | |
US6723750B2 (en) | Photodynamic therapy for pre-melanomas | |
Calzavara‐Pinton et al. | Photodynamic therapy: update 2006 Part 2: Clinical results | |
JP5612246B2 (ja) | 改良された光増感剤処方物およびそれらの用途 | |
JP2014094963A (ja) | アミノレブリン酸およびその誘導体の使用 | |
WO1991001727A2 (en) | Method of detection and treatment of malignant and non-malignant lesions by photochemotherapy | |
Silva et al. | Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic | |
US20060265028A1 (en) | Hair growth | |
Harvey et al. | Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398 | |
EP1626772B1 (en) | Improved photosensitizers application protocols | |
US20050215524A1 (en) | Methods and compositions for improving photodynamic therapy through administration of lipids | |
RU2674025C1 (ru) | Лекарственное средство на основе порфиринового фотосенсибилизатора копропорфирина для лечения рака кожи методом фотодинамической терапии | |
WO2009093144A2 (en) | Photodynamic therapy of sebaceous gland disorders | |
Babilas et al. | Photodynamic therapy | |
US20030083324A1 (en) | Photosensitizing ointment | |
Poljački et al. | Topical photodynamic therapy | |
CN116685319A (zh) | 用于治疗皮肤转移性癌的方法 | |
Lee et al. | A case of Bowen's disease partially responded to photodynamic therapy | |
US20050265954A1 (en) | Novel association, a method of its preparation and its uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101012 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110112 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110311 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110412 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20111215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120423 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120509 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120713 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121001 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140107 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140708 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140904 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5612246 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |